Credit: Panchenko Vladimir/Shutterstock. Navigator Medicines has secured $100m in a Series A financing round jointly led by RA Capital Management and Forbion to advance bispecific antibody ...
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is in the process of developing its anti-Tau antibody VY7523 for the treatment of patients with Alzheimer's Disease [AD] in a phase 1a single-ascending ...